Sealy

SEAL Therapeutics is a Swiss biotechnology company dedicated to developing a transformative gene therapy for LAMA2-related muscular dystrophy (LAMA2 MD), a severe and life-threatening genetic disease. The company's proprietary SEAL technology utilizes an adeno-associated virus (AAV) vector to deliver specifically designed artificial linker proteins that compensate for the absence of laminin-alpha 2 in muscle fibers. This innovative approach aims to stabilize muscle tissue and improve muscle function, addressing the underlying molecular cause of the disease rather than just its symptoms. Founded as a spin-off from the Biozentrum of the University of Basel, SEAL Therapeutics is currently advancing its lead program through preclinical development with the goal of initiating clinical trials in collaboration with pharmaceutical partners.